Prosidyan entered into a joint collaboration and license agreement with MO-SCI to further development of boron-based bioactive glass material for use in spinal and trauma applications.
The technology was initially developed at the University of Missouri, and is protected by an intellectual property portfolio comprising 12 U.S. patents. Prosidyan seeks to create a new generation of bioactive glass products using Aeridyan, the trade name for the boron-based bioactive glass material.
In 4Q15, Prosidyan received FDA 510(k) clearance to market FIBERGRAFT BG Morsels, an ultra-porous bone graft substitute comprising 45S5 Bioactive Glass microfibers and microspheres for use in posterolateral spinal fusion.
Prosidyan entered into a joint collaboration and license agreement with MO-SCI to further development of boron-based bioactive glass material for use in spinal and trauma applications.
The technology was initially developed at the University of Missouri, and is protected by an intellectual property portfolio comprising 12 U.S. patents....
Prosidyan entered into a joint collaboration and license agreement with MO-SCI to further development of boron-based bioactive glass material for use in spinal and trauma applications.
The technology was initially developed at the University of Missouri, and is protected by an intellectual property portfolio comprising 12 U.S. patents. Prosidyan seeks to create a new generation of bioactive glass products using Aeridyan, the trade name for the boron-based bioactive glass material.
In 4Q15, Prosidyan received FDA 510(k) clearance to market FIBERGRAFT BG Morsels, an ultra-porous bone graft substitute comprising 45S5 Bioactive Glass microfibers and microspheres for use in posterolateral spinal fusion.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
